1. Home
  2. AUPH

as 09-18-2025 1:31pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Founded: 1993 Country:
Canada
Canada
Employees: N/A City: EDMONTON
Market Cap: 1.4B IPO Year: 1999
Target Price: $12.00 AVG Volume (30 days): 1.5M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.42 EPS Growth: N/A
52 Week Low/High: $6.55 - $12.90 Next Earning Date: 11-06-2025
Revenue: $260,111,000 Revenue Growth: 25.59%
Revenue Growth (this year): 16.92% Revenue Growth (next year): 14.43%

AUPH Daily Stock ML Predictions

Share on Social Networks: